Danaher’s Leica Biosystems Completes StatLab Acquisition

Leica Biosystems, the anatomic and digital pathology business owned by Danaher, has completed its acquisition of privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity. The acquisition closed on September 28, 2026, bringing StatLab into Leica Biosystems roughly two and a half months after the deal was first announced. Financial terms were not disclosed.

The purchase adds a business centered on pathology consumables and equipment to Leica Biosystems, whose portfolio already spans tissue preparation, staining, digital slide scanning and computational pathology. Leica said the expanded offering will cover more of the laboratory workflow, from specimen collection and preparation through advanced staining, digital imaging and AI-enabled diagnosis.

Leica announced the acquisition agreement on July 14, saying at the time that StatLab would become part of Leica Biosystems after closing. The original announcement called for completion by the end of 2026, subject to customary conditions and applicable regulatory clearances. Monday’s close therefore moves the business from a pending acquisition into Danaher’s operating portfolio ahead of that stated year-end timetable.

StatLab adds recurring sales and a broad histology portfolio

StatLab supplies products used throughout the histology process, including specimen containers, tissue-processing materials, cassettes, microscope slides, coverslips, reagents, stains and laboratory equipment. Leica has described the company as a provider across the pre-analytical and analytical parts of the pathology workflow, areas that sit before and alongside the imaging and digital-analysis technologies for which Leica is also known.

The financial profile helps explain why StatLab fits Danaher’s diagnostics strategy. In its second-quarter materials, Danaher said StatLab generated about $250 million of revenue in 2025 and that more than 85% of its revenue was recurring. Danaher also said it expects the business to produce high-single-digit long-term core sales growth and to add to adjusted diluted earnings per share in the first full year of ownership. Those expectations were disclosed while the acquisition was still pending in Danaher’s July 21 earnings materials.

Recurring revenue is particularly relevant in a business built around laboratory consumables because those products are purchased repeatedly as specimens move through routine workflows. That gives StatLab a different revenue mix from large diagnostic instruments that may be purchased less frequently. Danaher has not disclosed a purchase price, so investors do not yet have a public acquisition multiple to compare with the growth and earnings contribution management expects.

StatLab has also been expanding its manufacturing capabilities. In 2024, the company said a new 35,000-square-foot facility in Arlington, Texas, added U.S. injection-molding capacity for histology consumables such as cassettes and brought its in-house manufacturing network at that time to six locations across the United States, United Kingdom and Germany. The company has used acquisitions of pathology-product manufacturers to broaden its product range and international reach as well.

The acquisition extends Leica’s reach across the pathology workflow

The strategic fit is less about adding another standalone instrument line and more about covering additional steps that occur before a pathology image reaches a scanner or software platform. StatLab’s products are used in specimen collection, fixation, processing, embedding, sectioning, slide preparation and staining. Leica’s portfolio extends into staining systems, digital pathology scanners and software used to manage and analyze tissue images.

With StatLab inside Leica Biosystems, Danaher can offer products across a larger portion of that sequence. Leica said the goal is to help laboratories improve consistency and standardization as they handle rising case volumes and more complex diagnostic work. The company also tied the acquisition to its push into computational pathology and AI-enabled diagnostics, where image quality and standardized upstream laboratory processes can affect the material ultimately presented for digital review.

That broader workflow position does not mean every StatLab product will be tied directly to Leica hardware or software. StatLab has historically sold a wide catalog to pathology laboratories, including products compatible with equipment from multiple manufacturers. The immediate change is ownership: StatLab is now part of Leica Biosystems and, through Leica, part of Danaher’s Diagnostics business.

Closing shifts attention from approvals to operating performance

The September 28 close removes the main uncertainty that remained after the July announcement: whether and when the acquisition would satisfy its closing conditions. Leica’s latest release said the businesses remain focused on supporting customers as they come together, while emphasizing the expanded portfolio rather than announcing changes to StatLab’s products, brands or customer channels.

For Danaher, the financial test now moves to execution. Management’s existing targets call for high-single-digit long-term core sales growth from StatLab and adjusted EPS accretion in the first full year under Danaher ownership. Because the acquisition closed near the end of September, 2027 will be the first full calendar year in which StatLab is owned by Danaher, making that period the clearest reference point for the earnings expectation disclosed in July.

The company has not provided a new revenue forecast, synergy target or purchase price with the closing announcement. That leaves StatLab’s roughly $250 million of 2025 revenue, its greater-than-85% recurring revenue mix and Danaher’s previously stated growth and earnings expectations as the main quantitative benchmarks available for evaluating the acquisition after closing.